Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications.

@article{Li2009CrosstalkOV,
  title={Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications.},
  author={Ji-Liang Li and Adrian L. Harris},
  journal={Frontiers in bioscience},
  year={2009},
  volume={14},
  pages={
          3094-110
        }
}
Angiogenesis is regulated by a number of angiogenic factors through many signalling pathways. The VEGF pathway and Notch signalling are perhaps two of the most important mechanisms in regulation of embryonic vascular development and tumour angiogenesis. Blockade of the VEGF pathway effectively inhibits tumour angiogenesis and growth in preclinical models. The successes in phase III trials have added anti-VEGF agents to standard cancer therapy in several major cancers. A recent flurry of… 

Figures from this paper

Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here?
TLDR
This review assesses the role of modulating VEGFR activity in cancer and systematically examines current evidence and trials in this area and identifies new therapeutic strategies which may be used in combination with V EGFR inhibitors to augment the efficacy of anti-angiogenic cancer treatments.
DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
TLDR
The findings show the importance of classifying mechanisms involved in angiogenesis in tumors, and how combination therapy to block DLL4-Notch signaling may enhance the efficacy of VEGF inhibitors, particularly in D LL4-upregulated tumors, will provide a rational base for the development of novel strategies to overcome antiangiogenic resistance in the clinic.
Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway.
TLDR
The results elucidate a novel mechanism by which the interplay between AML and endothelial cells promotes angiogenesis through the Notch/Dll4 pathway and hold promise as a novel antiangiogenic strategy for the treatment of AML.
Tumor and Stem Cell Biology DLL 4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo
TLDR
The findings show the importance of classifying mechanisms involved in angiogenesis in tumors, and how combination therapy to block DLL4Notch signaling may enhance the efficacy of VEGF inhibitors, particularly in D LL4-upregulated tumors, provide a rational base for the development of novel strategies to overcome antiangiogenic resistance in the clinic.
Angiogenic signaling aberrantly induced by tumor hypoxia.
Tumor growth, invasion and metastasis are largely dependent on the development of tumor vasculature. A great number of pro- and antiangiogenic molecules, have been identified. Bone marrow-derived
Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth
TLDR
It is concluded that DLL4 and JAG1 promote tumour growth by modulating tumour angiogenesis via different mechanisms, and anti-JAG1 therapy should be explored in conjunction with anti-DLL4 treatment in developing anti-Notch therapies in clinics.
Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer.
TLDR
It is established that Dll 4 plays a functionally important role in both the tumor and endothelial compartments of ovarian cancer and that targeting Dll4 in combination with anti-VEGF treatment might improve outcomes of ovariancancer treatment.
Antiangiogenic agents and targets: A perspective.
Epidermal Growth Factor Receptor Inhibition Reduces Angiogenesis via Hypoxia-Inducible Factor-1α and Notch1 in Head Neck Squamous Cell Carcinoma
TLDR
Targeting EGFR by suppressing hypoxia- and Notch-induced angiogenesis may benefit HNSCC therapy, as EGFR is involved in the tumorAngiogenesis of H NSCC via the HIF-1α and NotCh1 pathways.
Endothelial Krüppel-like Factor 4 Regulates Angiogenesis and the Notch Signaling Pathway*
TLDR
This work shows that Krüppel-like factor 4 (KLF4) is a central regulator of sprouting angiogenesis via regulating Notch and rescue Notch target gene expression and the KLF4 sproutingAngiogenesis phenotype by supplementation of DLL4 recombinant protein.
...
...

References

SHOWING 1-10 OF 136 REFERENCES
Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells.
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
TLDR
It is reported that VEGF dynamically regulates tumour endothelial expression of Delta-like ligand 4 (Dll4), which was previously shown to be absolutely required for normal embryonic vascular development, and blockade resulted in markedly increased tumour vascularity, associated with enhanced angiogenic sprouting and branching.
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
TLDR
It is demonstrated that inhibition of the action of an angiogenic factor spontaneously produced by tumour cells may suppress tumour growth in vivo.
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
TLDR
It is shown that Dll4-mediated Notch signalling has a unique role in regulating endothelial cell proliferation and differentiation, and is crucial during active vascularization, but less important for normal vessel maintenance.
Regulation of Notch1 and Dll4 by Vascular Endothelial Growth Factor in Arterial Endothelial Cells: Implications for Modulating Arteriogenesis and Angiogenesis
TLDR
It is shown here that vascular endothelial growth factor but not basic fibroblast growth factor can induce gene expression of Notch1 and its ligand, Delta-like 4 (Dll4), in human arterial endothelial cells.
Delta-like 4/Notch Signaling and Its Therapeutic Implications
TLDR
Dll4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy, especially when resistance to and/or escape from existing therapies evolve.
VEGF as a Key Mediator of Angiogenesis in Cancer
TLDR
The production of VEGF and other growth factors by the tumor results in the ‘angiogenic switch’, where new vasculature is formed in and around the tumor, allowing it to grow exponentially.
Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
TLDR
It is shown that DLL4, when expressed in tumor cells, functions as a negative regulator of tumor angiogenesis by reducing the number of blood vessels in all five types of xenografts, but acts as a positive driver for tumor growth in two of them (human glioblastoma and prostate cancer).
Vascular endothelial growth factor: basic science and clinical progress.
TLDR
Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen in vitro and an angiogenic inducer in a variety of in vivo models and is implicated in intraocular neovascularization associated with diabetic retinopathy and age-related macular degeneration.
...
...